CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

An aide to U.S. Health Secretary Robert F. Kennedy Jr. is seeking more information about three vaccines recommended by a ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

GSK claims that Pfizer’s FDA-approved vaccine for respiratory syncytial virus infringes on four patents protecting its own approved vaccine, Arexvy. The patent suit comes with the RSV season ...

Both companies saw sales of their RSV vaccines for adults tumble ... After the FDA approved GSK’s Arexvy and Pfizer’s Abrysvo in 2023, the CDC recommended the shots for all people 60 and ...

The U.S. Centers for Disease Control and Prevention’s vaccine ... disease, Pfizer (NYSE:PFE) said on Wednesday. This decision includes Abrysvo, approved for the prevention of RSV-related ...

If the FDA deems Pfizer’s and Moderna’s ... said the change is unlikely to affect brand-new vaccines. But it could have major ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE ... its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV ...

is pending final approval by the director of the CDC and the Department of Health and Human Services. Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and ...